文献速递癫痫

以高清晰度精准医学应对癫痫:综述

Tackling Epilepsy With High-definition Precision Medicine: A Review.
PubMed 文献 · JAMA Neurol · 2019-01-01

本文综述指出,癫痫精准医学目前多聚焦于减少发作,单靶点治疗仅惠及少数遗传性癫痫患者;提出高清晰度医学应整合人工智能与行为、环境、分子基因组、时型和微生物组数据,兼顾共病与网络功能,为每例患者提供最佳个体化治疗。

要点

  • 单分子通路治疗可减少发作频率,但难以解决癫痫相关多共病。
  • 高清晰度医学需融合人工智能与多维度个体化数据来优化治疗。
  • 精准医学应兼顾发作控制与神经发育、神经精神共病。

核心结论

  • 高清晰度精准医学需整合人工智能与行为、环境、分子基因组、时型和微生物组数据,为每例癫痫患者提供最佳个体化治疗。

研究设计与样本

  • 本文为综述,检索范围未在原文摘要中报告。

主要发现

  • 测序技术进步推动了癫痫遗传发现,为单基因癫痫提供精准医学靶点。
  • 单基因癫痫通常仅占所有癫痫类型的小部分,且当前精准医学主要聚焦于减少发作。
  • 仅关注发作可能忽视神经发育和神经精神共病,这些共病可能比发作本身更具挑战。

临床怎么用

  • 准确分子诊断仍是发展癫痫精准医学迭代过程的第一步。
  • 治疗可考虑超越发作减少,兼顾网络功能与共病的全景式干预。

局限性

  • 单分子通路靶向治疗可能减少发作频率,但不太可能解决涉及异常神经网络的多重共病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Various types of epilepsy are a leading cause of neurological disability worldwide; they have in common a propensity to recurrent unprovoked seizures. There is increasing interest in the concept of precision medicine for therapy. While treatment aimed at the level of an ion channel or single pathway has provided benefits for a small number of individuals with genetically mediated cases, a high-definition approach extending beyond genes to a broader array of personalized factors may improve outcomes. OBSERVATIONS: Advances in sequencing technologies have driven genetic discovery in epilepsy. This has provided targets for precision medicine in monogenic types of epilepsy. However, these typically represent a small subset of all types of epilepsy, and to date, precision medicine in epilepsy has primarily focused on seizure reduction. Such a unifocal view may overlook neurodevelopmental and neuropsychiatric comorbidities, which can be more challenging than the seizures themselves. Therefore, a panoramic approach to treatment encompassing both molecular diagnostic techniques and amelioration of network function by addressing factors beyond seizure reduction may be considered as part of a high-definition approach to tackling epilepsy. CONCLUSIONS AND RELEVANCE: High-definition medicine will require the development of analytical techniques, including artificial intelligence, that use and combine behavioral, environmental, molecular genomic, chronotype, and microbiomic data to offer the best individualized therapeutic options for disease management in each person with epilepsy. While an accurate molecular diagnosis remains the first step of the iterative process to the development of a precision medicine for an epilepsy, treatment targeted at a single molecular pathway may reduce seizure frequency but are not likely to address the multiple comorbidities associated with involved aberrant neural networks. To provide an improvement in precision medicine for epilepsy, a high-definition approach may be required that encompasses a panoramic view of factors that can be manipulated either directly or indirectly, now and in the future.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Kearney H, Byrne S, Cavalleri GL, et al. Tackling Epilepsy With High-definition Precision Medicine: A Review. JAMA Neurol. 2019. PMID: 31380988. doi:10.1001/jamaneurol.2019.2384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。